Castrate-Resistant Prostate Cancer Market is expected to grow and reach USD 29.79 billion by 2034 with a CAGR of 8.7% | PMR
January 02, 2025 06:50 ET
|
Polaris Market Research & Consulting LLP
New York, USA, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Market Overview With a CAGR of 8.7% from 2025 to 2034, the global castrate-resistant prostate cancer market is expected to increase from USD 14.04...
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
December 19, 2024 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
December 16, 2024 16:01 ET
|
Candel Therapeutics
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
Candel Therapeutics Announces Pricing of Public Offering
December 12, 2024 23:00 ET
|
Candel Therapeutics
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
Candel Therapeutics Announces $80 Million Proposed Public Offering
December 12, 2024 16:51 ET
|
Candel Therapeutics
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
December 10, 2024 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
December 09, 2024 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.
Asia-Pacific Radiation Oncology Market Analysis Report 2025-2030 - External Beam Radiation Therapy (EBRT) Dominated the Market with a Revenue Share of 35.9% in 2024
November 26, 2024 05:18 ET
|
Research and Markets
Dublin, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Radiation Oncology Market Size, Share & Trends Analysis Report by Type (External Beam Radiation Therapy, Internal Beam Radiation...
Liquid Biopsy Market Size to Worth USD 28.84 Billion by 2033 | Straits Research
November 21, 2024 09:55 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, Nov. 21, 2024 (GLOBE NEWSWIRE) -- "Liquid biopsy" isolates and detects circulating nucleic acids (DNA or RNA), exosomes, and circulating tumor cells to diagnose primary...
KOELIS announces the first interim results of the VIOLETTE trial which evaluates the use of OBT-Fusion® technology in focal ablation of the prostate by microwave needles
November 20, 2024 09:00 ET
|
Koelis
GRENOBLE, France, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a global leader and innovator in prostate care, announced today passing an important...